Literature DB >> 19211122

Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model.

Anurag Sharma1, Dinesh S Bangari, Manish Tandon, Aseem Pandey, Harm HogenEsch, Suresh K Mittal.   

Abstract

Nonhuman adenoviruses including bovine adenovirus serotype 3 (BAd3) and porcine adenovirus serotype 3 (PAd3) can circumvent pre-existing immunity against human adenovirus serotype 5 (HAd5) and are being developed as alternative vectors for gene delivery. To assess the usefulness of these vectors for in vivo gene delivery, we compared biodistribution, persistence, state of vector genome, and transgene and vector gene expression by replication-defective BAd3 and PAd3 vectors with those of HAd5 vector in a FVB/n mouse model following intravenous inoculation. BAd3 vector efficiently transduced the heart, kidney and lung in addition to the liver and spleen and persisted for a longer duration compared to PAd3 or HAd5 vectors. Biodistribution of PAd3 vector was comparable to that of HAd5 vector but showed more rapid vector clearance. Only linear episomal forms of BAd3, PAd3, and HAd5 vector genomes were detected. All three vectors efficiently expressed the green fluorescent protein (GFP) transgene proportionate to the vector genome copy number in various tissues. Furthermore, leaky expression of vector genes, both the early (E4) and the late (hexon) was observed in all three vectors and gradually declined with time. These results suggest that BAd3 and PAd3 vectors could serve as an alternative or supplement to HAd5 for gene delivery applications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19211122      PMCID: PMC2728445          DOI: 10.1016/j.virol.2009.01.008

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  62 in total

Review 1.  Update on adenovirus and its vectors.

Authors:  W C Russell
Journal:  J Gen Virol       Date:  2000-11       Impact factor: 3.891

2.  CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors.

Authors:  R Alemany; D T Curiel
Journal:  Gene Ther       Date:  2001-09       Impact factor: 5.250

3.  Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells.

Authors:  Anna Kanerva; Galina V Mikheeva; Victor Krasnykh; Candace J Coolidge; John T Lam; Parameshwar J Mahasreshti; Shannon D Barker; Michael Straughn; Mack N Barnes; Ronald D Alvarez; Akseli Hemminki; David T Curiel
Journal:  Clin Cancer Res       Date:  2002-01       Impact factor: 12.531

4.  Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy.

Authors:  S Moffatt; J Hays; H HogenEsch; S K Mittal
Journal:  Virology       Date:  2000-06-20       Impact factor: 3.616

5.  Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver.

Authors:  N Tao; G P Gao; M Parr; J Johnston; T Baradet; J M Wilson; J Barsoum; S E Fawell
Journal:  Mol Ther       Date:  2001-01       Impact factor: 11.454

6.  Replication-defective vector based on a chimpanzee adenovirus.

Authors:  S F Farina; G P Gao; Z Q Xiang; J J Rux; R M Burnett; M R Alvira; J Marsh; H C Ertl; J M Wilson
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

7.  Characterization of bovine adenovirus type 3 E1 proteins and isolation of E1-expressing cell lines.

Authors:  Alberto L van Olphen; Suresh K Tikoo; Suresh K Mittal
Journal:  Virology       Date:  2002-03-30       Impact factor: 3.616

8.  Porcine adenovirus-3 as a helper-dependent expression vector.

Authors:  P Seshidhar Reddy; Neeraja Idamakanti; Lorne A Babiuk; Majid Mehtali; Suresh K Tikoo
Journal:  J Gen Virol       Date:  1999-11       Impact factor: 3.891

9.  In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor.

Authors:  Theodore Smith; Neeraja Idamakanti; Helen Kylefjord; Michele Rollence; Laura King; Michele Kaloss; Michael Kaleko; Susan C Stevenson
Journal:  Mol Ther       Date:  2002-06       Impact factor: 11.454

10.  An adenovirus serotype 5 vector with fibers derived from ovine atadenovirus demonstrates CAR-independent tropism and unique biodistribution in mice.

Authors:  Masaharu Nakayama; Gerald W Both; Boglarka Banizs; Yuko Tsuruta; Seiji Yamamoto; Yosuke Kawakami; Joanne T Douglas; Kenzaburo Tani; David T Curiel; Joel N Glasgow
Journal:  Virology       Date:  2006-03-03       Impact factor: 3.616

View more
  26 in total

Review 1.  Oncolytic viruses: From bench to bedside with a focus on safety.

Authors:  Pascal R A Buijs; Judith H E Verhagen; Casper H J van Eijck; Bernadette G van den Hoogen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  155R is a novel structural protein of bovine adenovirus type 3, but it is not essential for virus replication.

Authors:  Ahmed O Hassan; Sai V Vemula; Anurag Sharma; Dinesh S Bangari; Krishna K Mishra; Suresh K Mittal
Journal:  J Gen Virol       Date:  2017-04-27       Impact factor: 3.891

3.  Persistence and the state of bovine and porcine adenoviral vector genomes in human and nonhuman cell lines.

Authors:  Anurag Sharma; Dinesh S Bangari; Sai V Vemula; Suresh K Mittal
Journal:  Virus Res       Date:  2011-08-16       Impact factor: 3.303

4.  Preclinical studies for pharmacokinetics and biodistribution of Ad-stTRAIL, an adenovirus delivering secretable trimeric TRAIL for gene therapy.

Authors:  Chae Young Kim; Soon Hye Park; Moonsup Jeong; O Seo Kwon; Hyounmie Doh; Su Hyung Kang; Paul D Robbins; Byong Moon Kim; Dai Wu Seol; Byung Gee Kim
Journal:  Exp Mol Med       Date:  2011-10-31       Impact factor: 8.718

5.  Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model.

Authors:  Anurag Sharma; Dinesh S Bangari; Manish Tandon; Harm Hogenesch; Suresh K Mittal
Journal:  Virus Res       Date:  2010-07-24       Impact factor: 3.303

6.  Maternal immunization with chimpanzee adenovirus expressing RSV fusion protein protects against neonatal RSV pulmonary infection.

Authors:  Anurag Sharma; Rebecca Wendland; Biin Sung; Wenzhu Wu; Thomas Grunwald; Stefan Worgall
Journal:  Vaccine       Date:  2014-08-26       Impact factor: 3.641

Review 7.  Strategies to overcome host immunity to adenovirus vectors in vaccine development.

Authors:  Erin E Thacker; Laura Timares; Qiana L Matthews
Journal:  Expert Rev Vaccines       Date:  2009-06       Impact factor: 5.217

Review 8.  Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Authors:  Estrella Lopez-Gordo; Iva I Podgorski; Nicholas Downes; Ramon Alemany
Journal:  Hum Gene Ther       Date:  2014-03-25       Impact factor: 5.695

9.  Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses.

Authors:  A Sharma; M Tandon; Y S Ahi; D S Bangari; R Vemulapalli; S K Mittal
Journal:  Gene Ther       Date:  2010-02-18       Impact factor: 5.250

Review 10.  Adenovirus receptors and their implications in gene delivery.

Authors:  Anurag Sharma; Xiaoxin Li; Dinesh S Bangari; Suresh K Mittal
Journal:  Virus Res       Date:  2009-02-26       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.